What’s the current market cap for BioCryst stock?

BioCryst (BCRX) has a market cap of $2.2B as of May 22, 2026.

What is the P/E ratio for BioCryst stock?

The price to earnings (P/E) ratio for BioCryst (BCRX) stock is 0 as of May 22, 2026.

Does BioCryst stock pay dividends?

No, BioCryst (BCRX) stock does not pay dividends to its shareholders as of May 22, 2026.

When is the next BioCryst dividend payment date?

BioCryst (BCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioCryst?

BioCryst (BCRX) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy BioCryst stock | $BCRX Share Price

13:30

15:10

16:45

18:25

20:00

About BioCryst

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Ticker

$BCRX

Sector

Health

Primary listing

NASDAQ

Employees

435

Headquarters

Durham, United States

Website

www.biocryst.com

BioCryst Metrics

BasicAdvanced

$2.2bn

-$2.10

0.57

What the Analysts think about BioCryst

Analyst ratings (Buy, Hold, Sell) for BioCryst stock.

Bulls say / Bears say

BioCryst reported Q2 2025 revenue of $163.4 million and ORLADEYO sales of $156.8 million—up 45% year-over-year—showing sustained commercial strength through midyear.

Full-year 2025 ORLADEYO net revenue grew 38% year-over-year to $601.8 million, surpassing the $590–600 million guidance range and emphasizing strong demand and pricing power.

In January 2026, BioCryst completed its $700 million acquisition of Astria Therapeutics, adding the Phase 3 injectable navenibart to its hereditary angioedema portfolio and diversifying its pipeline in rare diseases.

Evercore ISI downgraded BioCryst, highlighting intensifying competition in the hereditary angioedema (HAE) market and warning that ORLADEYO may find it difficult to maintain market share in a 'zero-sum' environment.

Analysts point out that BioCryst is heavily dependent on ORLADEYO for almost all of its revenue, representing significant concentration risk should competing HAE therapies gain traction or if pricing power diminishes.

Key late-stage pipeline assets—including navenibart (Phase 3) and BCX17725 (Phase 1)—have clinical data readouts scheduled for late 2026 and beyond, postponing major catalysts and increasing execution risk.

Data summarised monthly by Lightyear AI. Last updated on 25 Apr 2026.

BioCryst Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

BioCryst Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCRX

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

BioCryst reported Q2 2025 revenue of $163.4 million and ORLADEYO sales of $156.8 million—up 45% year-over-year—showing sustained commercial strength through midyear.

Full-year 2025 ORLADEYO net revenue grew 38% year-over-year to $601.8 million, surpassing the $590–600 million guidance range and emphasizing strong demand and pricing power.

Data summarised monthly by Lightyear AI. Last updated on 25 Apr 2026.